Oliver Spandow - Nephros Director
| NEPH Stock | USD 2.19 0.05 2.34% |
Director
Mr. Oliver Spandow is Director of the company. He is currently the CFO, Executive Vice President and a member of the board of directors of IDOC, LLC, an optometrybased consulting and member service organization. Prior to IDOC, Mr. Spandow spent 15 years with Johnson and Johnson, including roles as the General Manager of the JNJ Vision Care business in the United Kingdom and Ireland, Vice President of Strategic Accounts and Business Insights at Vistakon USA, and Vice President, Finance and CFO of Vistakon USA. While at JNJ, in addition to general finance, sales and marketing roles, he was involved with multiple acquisitions, divestment, and licensing deals. Prior to JJ, Mr. Spandow was a Management Consultant with Price Waterhouse since 2018.
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | 380 Lackawanna Place, South Orange, NJ, United States, 07079 |
| Phone | 201 343 5202 |
| Web | https://www.nephros.com |
Oliver Spandow Latest Insider Activity
Tracking and analyzing the buying and selling activities of Oliver Spandow against Nephros stock is an integral part of due diligence when investing in Nephros. Oliver Spandow insider activity provides valuable insight into whether Nephros is net buyers or sellers over its current business cycle. Note, Nephros insiders must abide by specific rules, including filing SEC forms every time they buy or sell Nephros'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Oliver Spandow over three months ago Acquisition by Oliver Spandow of 14294 shares of Nephros subject to Rule 16b-3 |
Nephros Management Efficiency
The company has return on total asset (ROA) of (0.0871) % which means that it has lost $0.0871 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1827) %, meaning that it created substantial loss on money invested by shareholders. Nephros' management efficiency ratios could be used to measure how well Nephros manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.16. The current Return On Capital Employed is estimated to decrease to -0.17. As of now, Nephros' Asset Turnover is increasing as compared to previous years.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Roland Hess | Straumann Holding AG | 64 | |
| Noripah Kamso | Top Glove | 57 | |
| Beat Luethi | Straumann Holding AG | 56 | |
| Carsten Hellmann | Coloplast A | 53 | |
| James Beeson | Utah Medical Products | 75 | |
| Scott Shuda | InfuSystems Holdings | 52 | |
| Neal Goldman | Milestone Scientific | 74 | |
| Leonard Schiller | Milestone Scientific | 73 | |
| Per Magid | Coloplast A | 73 | |
| Rainer Althoff | Top Glove | 67 | |
| Paul Richins | Utah Medical Products | 56 | |
| Barbara Payne | Utah Medical Products | 70 | |
| Monique Bourquin | Straumann Holding AG | 52 | |
| Thomas Barfod | Coloplast A | 53 | |
| Birgitte Nielsen | Coloplast A | 54 | |
| Edward Zelnick | Milestone Scientific | 68 | |
| Mohd Hassan | Top Glove | 63 | |
| Utama Ayub | Top Glove | 86 | |
| Torben Rasmussen | Coloplast A | 57 | |
| Ernst Hoyer | Utah Medical Products | 79 | |
| Sven Bjorklund | Coloplast A | 59 | |
Management Performance
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0871 |
Nephros Leadership Team
Elected by the shareholders, the Nephros' board of directors comprises two types of representatives: Nephros inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nephros. The board's role is to monitor Nephros' management team and ensure that shareholders' interests are well served. Nephros' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nephros' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Malcom Persen, Director | ||
| Vashone Thomas, Regulatory, Quality | ||
| Thomas Gwydir, Director | ||
| Joleen Turner, VP Devel | ||
| Paul Mieyal, Director | ||
| Greg Lucas, President Systems | ||
| Robert Banks, CEO President | ||
| Alfred Vargas, Director Operations | ||
| Daron Evans, CEO and President Acting CFO, Director and Member of Audit Committee | ||
| Judy CFA, Chief Officer | ||
| Judy Mazzini, Controller | ||
| MS MBA, Inc Products | ||
| Andrew Astor, CFO, CEO | ||
| Alisa Lask, Director | ||
| Matthew Rosenberg, Director | ||
| Moshe Pinto, Director | ||
| Arthur Amron, Independent Director | ||
| Oliver Spandow, Director | ||
| Brianne McGuire, Marketing Brand |
Nephros Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nephros a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0871 | ||||
| Profit Margin | (0.11) % | ||||
| Operating Margin | (0.20) % | ||||
| Current Valuation | 20.62 M | ||||
| Shares Outstanding | 10.54 M | ||||
| Shares Owned By Insiders | 11.96 % | ||||
| Shares Owned By Institutions | 40.28 % | ||||
| Number Of Shares Shorted | 1.61 K | ||||
| Price To Earning | (4.51) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nephros. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Nephros Stock analysis
When running Nephros' price analysis, check to measure Nephros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nephros is operating at the current time. Most of Nephros' value examination focuses on studying past and present price action to predict the probability of Nephros' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nephros' price. Additionally, you may evaluate how the addition of Nephros to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is Nephros' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nephros. If investors know Nephros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nephros listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 1.371 | Quarterly Revenue Growth 0.272 | Return On Assets (0.09) | Return On Equity (0.18) |
The market value of Nephros is measured differently than its book value, which is the value of Nephros that is recorded on the company's balance sheet. Investors also form their own opinion of Nephros' value that differs from its market value or its book value, called intrinsic value, which is Nephros' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nephros' market value can be influenced by many factors that don't directly affect Nephros' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nephros' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nephros is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nephros' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.